Loading
Defined molecular response monitoring in CML and showed that many patients can safely stop imatinib.
Timothy Hughes led the molecular monitoring analyses of the IRIS trial that established BCR-ABL1 quantitative PCR and the International Scale as the way to track chronic myeloid leukaemia, and co-led ENESTnd (nilotinib) and the studies of treatment-free remission showing about half of patients in deep molecular response can stop tyrosine kinase inhibitors. He has chaired the International CML Foundation.
Shares IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia, Chronic myeloid leukaemia (CML), Imatinib.
Shares Chronic myeloid leukaemia (CML), Imatinib, Small-molecule kinase inhibitors.
Shares Chronic myeloid leukaemia (CML), Imatinib and the tag cml.
Shares Chronic myeloid leukaemia (CML), Imatinib, Small-molecule kinase inhibitors.
Shares Chronic myeloid leukaemia (CML), Imatinib, Small-molecule kinase inhibitors.
Shares Chronic myeloid leukaemia (CML), Imatinib, Small-molecule kinase inhibitors.
Shares Imatinib, Small-molecule kinase inhibitors.
Shares Imatinib, Small-molecule kinase inhibitors.